Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9737304 | 0.89 | ALDH1A1 (0.52) | TPMTALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL21939457 | 0.83 | ALDH1A1 (0.39) | TPMTALDH1A1MAPK1SMN1; SMN2DPP4 | |
| SCHEMBL11429956 | 0.82 | ALDH1A1 (0.38) | TPMTALDH1A1MAPK1SMN1; SMN2DPP4 | |
| SCHEMBL7270831 | 0.80 | ALDH1A1 (0.52) | TPMTALDH1A1KDM4ELMNAGPR35 | |
| SCHEMBL14339400 | 0.80 | KMT2A (0.42) | TPMTALDH1A1SMN1; SMN2LMNAGPR35 | |
| SCHEMBL5781652 | 0.80 | DPP4 (0.43) | TPMTALDH1A1MAPK1SMN1; SMN2DPP4 | |
| SCHEMBL111202 | 0.79 | AKR1C4 (0.54) | TPMTALDH1A1SMN1; SMN2DPP4HSD17B10 | |
| SCHEMBL8827322 | 0.79 | DPP4 (0.46) | TPMTALDH1A1MAPK1SMN1; SMN2DPP4 | |
| SCHEMBL21939510 | 0.79 | PTPN1 (0.51) | TPMTALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL7265798 | 0.78 | POLB (0.48) | TPMTALDH1A1SMN1; SMN2HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105859549-A | Method for synthesizing 2,6-dichloro p-toluic acid | 大连信科化工有限公司 | 2016-08-17 | — | — | CN | claimed |
| CN-118666664-A | Method for preparing p-methylbenzoic acid by catalyzing carbon dioxide and toluene | 中国石油化工股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-113698287-B | Method for preparing p-methylbenzoic acid by catalyzing carbon dioxide and toluene | 中国石油化工股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2022-08-30 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| CN-113698287-A | Method for preparing p-methylbenzoic acid by catalyzing carbon dioxide and methylbenzene | 中国石油化工股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2021-05-06 | — | — | US | disclosed |
| CN-107522664-B | Amino acid derivatives functionalized at the N-terminus capable of forming drug-encapsulated microspheres | 麻省理工学院 | 2021-03-16 | — | — | CN | disclosed |
| EP-3765005-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | The Regents of the University of California (US) | 2021-01-20 | — | — | EP | disclosed |
| US-6057346-A | USED TO DELAY OR SUPPRESS THE TRANSITION OF A RETROVIRAL INFECTION FROM A LATENT TO A VIRULENT CONDITION, THEREBY AMELIORATING RETROVIRALLY CAUSED DISEASES SUCH AS AIDS, ARE ALSO USEFUL IN CANCER TREATMENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-05-02 | — | — | US | disclosed |
| US-5744492-A | Method for inhibiting angiogenesis | UNITED STATES OF AMERICA (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0797438-A1 | INHIBITION OF RETROVIRAL LTR PROMOTERS BY CALCIUM RESPONSE MODIFIERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-10-01 | — | — | EP | disclosed |
| US-5565478-A | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996018394-A1 | INHIBITION OF RETROVIRAL LTR PROMOTERS BY CALCIUM RESPONSE MODIFIERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OFHEALTH AND HUMAN SERVICES (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995008327-A1 | METHOD FOR INHIBITING ANGIOGENESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-30 | — | — | WO | disclosed |
| WO-1995007695-A1 | METHOD FOR INHIBITING METALLOPROTEINASE EXPRESSION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0151529-B1 | 5-(AMINO OR SUBSTITUTED AMINO)-1,2,3-TRIAZOLES | MERCK & CO. INC. (US) | 1991-09-18 | — | — | EP | disclosed |
| US-4590201-A | ANTICOCCIDIAL AGENT FOR ANIMALS PARTICULARLY FOR POULTRY | MERCK & CO., INC. (US) | 1986-05-20 | — | — | US | disclosed |
| EP-0151529-A2 | 5-(Amino or substituted amino)-1,2,3-triazoles | MERCK & CO. INC. (US) | 1985-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR1, S1PR3, S1PR2 | TPMT 2223/4885ALDH1A1 2196/4885MAPK1 1447/4885 |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | TPMT 2119/4885ALDH1A1 382/4885MAPK1 3134/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | TPMT 2119/4885ALDH1A1 382/4885MAPK1 3134/4885 |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | TPMT 2223/4885ALDH1A1 2196/4885MAPK1 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.